New drug duo aims to outsmart resistant colon cancer

NCT ID NCT03446157

Summary

This study tested whether combining two targeted drugs, palbociclib and cetuximab, could help control advanced colon cancer that has spread. It involved 24 patients whose cancer had specific genetic features and who had already tried other treatments. The goal was to see if hitting the cancer with two different approaches at once could slow its growth better than standard therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina, 27599-7295, United States

Conditions

Explore the condition pages connected to this study.